表紙
市場調査レポート

アジア太平洋地域の季節性インフルエンザワクチン市場:政府支援のプラスの影響が、生産能力の限界や投資の増加、新規参入企業の障壁となる厳しい規制を相殺

Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants

発行 GBI Research 商品コード 226429
出版日 ページ情報 英文 137 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
アジア太平洋地域の季節性インフルエンザワクチン市場:政府支援のプラスの影響が、生産能力の限界や投資の増加、新規参入企業の障壁となる厳しい規制を相殺 Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants
出版日: 2013年04月08日 ページ情報: 英文 137 Pages
概要

アジア太平洋地域の季節性インフルエンザワクチン市場は、急速に成長している市場です。2018年までに18億7,900万米ドル規模に達する見込みで、2011年〜2018年のCAGRで9%の成長が予測されています。

当レポートでは、アジア太平洋地域の季節性インフルエンザワクチン市場について調査分析し、研究開発パイプラインに焦点を当てて、主要国の市場分析、市場予測、法規制環境、競合情勢、M&A活動なども含めて、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 市場概要

  • 市場の特徴と予測
  • 地域別収益

第4章 オーストラリア

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 促進要因と障壁

第5章 中国

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第6章 香港

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第7章 インド

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 促進要因と障壁

第8章 日本

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種人口
  • 促進要因と抑制要因

第9章 マレーシア

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第10章 ニュージーランド

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第11章 フィリピン

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第12章 シンガポール

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第13章 台湾

  • 登録手続きと法規制
  • 市場の特徴と予測
  • 予防接種の費用
  • 予防接種のパターン
  • 競合情勢
  • 促進要因と障壁

第14章 パイプライン分析

  • パイプライン分析:フェーズ別
  • 有望な分子製品プロファイル
  • 上市製品プロファイル

第15章 競合情勢

  • Sanofi Pasteur
  • GlaxoSmithKline Biologicals
  • Abbott Laboratories (Solvay Pharmaceuticals)
  • CSL Biotherapies
  • Novartis Vaccines
  • Crucell N.V. (Berna Biotech)

第16章 戦略的統合

  • 概要
  • 主なM&A取引
  • M&A取引:地域別
  • 主なライセンス契約
  • ライセンス取引:地域別

第17章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GBIHC264MR

Summary

GBI Research, the leading business intelligence provider has released its latest research "Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 - Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants" which essentially provides insights into the seasonal influenza vaccine sales forecasts for the Asia-Pacific Region until 2018. The report also delves deep into vaccination patterns for seasonal influenza in the Asia-Pacific Region. Further, the geographical distribution of seasonal influenza vaccines across Japan, Australia, New Zealand, China, Taiwan, Philippines, Hong Kong, Malaysia, India and Singapore are also provided in the report. The report offers a clear view of the regulatory landscape in the Asia-Pacific countries. The report also reveals the seasonal influenza vaccine R&D pipeline and offers profiles of promising vaccines. The report explores the competitive landscape including profiles for top companies. Finally, the key trend analysis on mergers and acquisitions, and licensing agreements involving seasonal influenza vaccines is also presented.

Treatment of seasonal influenza is dominated by two categories of treatment options, vaccines and antiviral therapies. In the recent years it was observed that demand for seasonal influenza vaccines have increased due to changed perception of patient population. The patient population is of the opinion that preventive healthcare is better compared to curative healthcare; this led to increased demand of vaccines in Asia-Pacific region. Asia-Pacific (APAC) region is an attractive market for seasonal influenza vaccine manufacturers. Major drivers in the market is increasing awareness, increasing vaccination coverage in the APAC countries and rising government support for immunization against seasonal influenza. Major restraints of the market are variable demand and limited production capacity. Traditional egg based manufacturing of seasonal influenza vaccines is being replaced with cell culture vaccines. Cell culture based production of vaccines is expected to reduce the problems associated with the production and use of seasonal influenza vaccines which will further increase the vaccination coverage in the APAC region.

GBI Research Analysis shows that the seasonal influenza vaccine market in the APAC Region is a fast growing market. This is due to increased vaccination coverage against seasonal influenza in the region. GBI Research forecasts the market to grow at double digit Compounded Annual Growth Rate (CAGR) of 9% during the period 2011-2018 from $1,015m in 2011 to $1,879m by 2018. This growth is driven by factors such as increasing awareness on influenza caused by threat of pandemic influenza, increasing vaccination coverage because of the governments' support, growing population in the APAC region and entry of novel vaccines and production technologies.

GBI Research finds that the Philippines' seasonal influenza vaccine market is the most attractive in the seasonal influenza vaccine market for Asia-Pacific region both in terms of value and growth rate. Other attractive markets in terms of growth rate are Malaysia's and Singapore's seasonal influenza vaccine markets. Australia's seasonal influenza vaccine market is also a large sized attractive market forecast to grow at a healthy growth rate during the period 2011-2018. In-depth analysis of the report is based on propriety databases, primary and secondary research and in house analysis by the GBI Research team of experts.

GBI Research analysis shows that the R&D pipeline for the seasonal influenza vaccines is moderately strong with approximately 50% of the pipeline in the Phase II and Phase III. The major vaccine manufacturers are focused upon acquiring new technologies and strengthening their presence in the market by collaborating with or acquiring small and medium sized biotech companies that have strong vaccine candidates in their pipeline. The R&D activity also indicates development of new technologies and novel vaccines that can revolutionize the market in near future.

Scope

  • The report analyses vaccination patterns, market characterization, regulatory landscape, pipeline analysis, competitive landscape and key M&A trends in the seasonal influenza vaccine market in the APAC region.
  • Data and analysis on the seasonal influenza vaccine market in the Asia-Pacific Region including Japan, Australia, New Zealand, China, Taiwan, Philippines, Malaysia, Hong Kong, India and Singapore.
  • Market forecasts for the seasonal influenza vaccines from 2011 to 2018
  • Market Data on geographical landscape including country wise vaccination coverage, public and private contribution on total doses, price of vaccine, market size and market share.
  • Key drivers and restraints that have created significant impact on the market.
  • Regulatory landscape including the pharmaceutical product approval process and overview of regulatory authorities in the countries in Asia-Pacific region
  • Competitive landscape of the seasonal influenza vaccine market in Asia-Pacific region including top companies profiles. The key companies studied in this report are Sanofi Pasteur, Abbott Laboratories, GlaxoSmithKline Biologicals, Novartis Vaccines, CSL Biotherapies and Crucell.
  • Key M&A activities, Licensing Agreements, that have taken place between 2007 and 2012 in the seasonal influenza vaccine market.

Reasons to buy

  • The report will aid business development and marketing executives strategizing their product launches -
  • Build effective strategies to launch their pipeline products by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that might probably fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of top competitors.
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class vaccines with more efficacy and better safety.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

3. Seasonal Influenza Vaccine Market in Asia-Pacific - Market Overview

  • 3.1. Market Characterization and Forecasts
  • 3.2. Revenue by Geographical Segmentation

4. Seasonal Influenza Vaccine Market in Asia-Pacific - Australia

  • 4.1. Registration Process and Regulations
  • 4.2. Market Characterization and Forecasts
  • 4.3. Cost of Vaccination
  • 4.4. Vaccination Pattern
    • 4.4.1. Population
    • 4.4.2. Vaccinated Population Contribution
    • 4.4.3. Vaccination Coverage
    • 4.4.4. Number of Doses per Person
    • 4.4.5. Total Number of Doses
    • 4.4.6. Dose Contribution
  • 4.5. Drivers and Barriers
    • 4.5.1. Drivers
    • 4.5.2. Restraints

5. Seasonal Influenza Vaccine Market in Asia-Pacific - China

  • 5.1. Registration Process and Regulations
  • 5.2. Market Characterization and Forecasts
  • 5.3. Cost of Vaccination
  • 5.4. Vaccination Pattern
    • 5.4.1. Population
    • 5.4.2. Vaccinated Population Contribution
    • 5.4.3. Vaccination Coverage
    • 5.4.4. Number of Doses per Person
    • 5.4.5. Total Number of Doses
    • 5.4.6. Dose Contribution
  • 5.5. Competitive Landscape
  • 5.6. Drivers and Barriers
    • 5.6.1. Drivers
    • 5.6.2. Barriers

6. Seasonal Influenza Vaccine Market in Asia-Pacific - Hong Kong

  • 6.1. Registration Process and Regulations
  • 6.2. Market Characterization and Forecasts
  • 6.3. Cost of Vaccination
  • 6.4. Vaccination Pattern
    • 6.4.1. Population
    • 6.4.2. Vaccinated Population Contribution
    • 6.4.3. Vaccination Coverage
    • 6.4.4. Number of Doses per Person
    • 6.4.5. Total Number of Doses
    • 6.4.6. Dose Contribution
  • 6.5. Competitive Landscape
  • 6.6. Drivers and Barriers
    • 6.6.1. Drivers
    • 6.6.2. Restraints

7. Seasonal Influenza Vaccine Market in Asia-Pacific - India

  • 7.1. Registration Process and Regulations
  • 7.2. Market Characterization and Forecasts
  • 7.3. Cost of Vaccination
  • 7.4. Drivers and Barriers
    • 7.4.1. Drivers
    • 7.4.2. Barriers

8. Seasonal Influenza Vaccine Market in Asia-Pacific - Japan

  • 8.1. Registration Process and Regulations
  • 8.2. Market Characterization and Forecasts
  • 8.3. Cost of Vaccination
  • 8.4. Vaccinated Population
    • 8.4.1. Population
    • 8.4.2. Vaccinated Population Contribution
    • 8.4.3. Vaccination Coverage
  • 8.5. Drivers and Restraints
    • 8.5.1. Drivers
    • 8.5.2. Barriers

9. Seasonal Influenza Vaccine Market in Asia-Pacific - Malaysia

  • 9.1. Registration Process and Regulations
  • 9.2. Market Characterization and Forecasts
  • 9.3. Cost of Vaccination
  • 9.4. Vaccination Pattern
    • 9.4.1. Population
    • 9.4.2. Vaccinated Population Contribution
    • 9.4.3. Vaccination Coverage
    • 9.4.4. Number of Doses per Person
    • 9.4.5. Total Number of Doses
    • 9.4.6. Dose Contribution
  • 9.5. Competitive Landscape
  • 9.6. Drivers and Barriers
    • 9.6.1. Drivers
    • 9.6.2. Barriers

10. Seasonal Influenza Vaccine Market in Asia-Pacific - New Zealand

  • 10.1. Registration Process and Regulations
  • 10.2. Market Characterization and Forecasts
  • 10.3. Cost of Vaccination
  • 10.4. Vaccination Pattern
    • 10.4.1. Population
    • 10.4.2. Vaccinated Population Contribution
    • 10.4.3. Vaccination Coverage
    • 10.4.4. Number of Doses per Person
    • 10.4.5. Total Number of Doses
    • 10.4.6. Dose Contribution
  • 10.5. Competitive Landscape
  • 10.6. Drivers and Barriers
    • 10.6.1. Drivers
    • 10.6.2. Barriers

11. Seasonal Influenza Vaccine Market in Asia-Pacific - Philippines

  • 11.1. Registration Process and Regulations
  • 11.2. Market Characterization and Forecasts
  • 11.3. Cost of Vaccination
  • 11.4. Vaccination Pattern
    • 11.4.1. Population
    • 11.4.2. Vaccinated Population Contribution
    • 11.4.3. Vaccination Coverage
    • 11.4.4. Number of Doses per Person
    • 11.4.5. Total Number of Doses
    • 11.4.6. Dose Contribution
  • 11.5. Competitive Landscape
  • 11.6. Drivers and Barriers
    • 11.6.1. Drivers
    • 11.6.2. Restraints

12. Seasonal Influenza Vaccine Market in Asia-Pacific - Singapore

  • 12.1. Registration Process and Regulations
  • 12.2. Market Characterization and Forecasts
  • 12.3. Cost of Vaccination
  • 12.4. Vaccination Pattern
    • 12.4.1. Population
    • 12.4.2. Vaccinated Population Contribution
    • 12.4.3. Vaccination Coverage
    • 12.4.4. Number of Doses per Person
    • 12.4.5. Total Number of Doses
    • 12.4.6. Dose Contribution
  • 12.5. Competitive Landscape
  • 12.6. Drivers and Barriers
    • 12.6.1. Drivers
    • 12.6.2. Barriers

13. Seasonal Influenza Vaccine Market in Asia-Pacific - Taiwan

  • 13.1. Registration Process and Regulations
  • 13.2. Market Characterization and Forecasts
  • 13.3. Cost of Vaccination
  • 13.4. Vaccination Pattern
    • 13.4.1. Population
    • 13.4.2. Vaccinated Population Contribution
    • 13.4.3. Vaccination Coverage
    • 13.4.4. Number of Doses per Person
    • 13.4.5. Total Number of Doses
    • 13.4.6. Dose Contribution
  • 13.5. Competitive Landscape
  • 13.6. Drivers and Barriers
    • 13.6.1. Drivers
    • 13.6.2. Restraints

14. Seasonal Influenza Vaccine Market in Asia-Pacific - Pipeline Analysis

  • 14.1. Pipeline Analysis by Phase
  • 14.2. Product Profiles of Promising Molecules
    • 14.2.1. Optaflu
    • 14.2.2. GSK2186877A
    • 14.2.3. Intanza/Flu-ID
    • 14.2.4. Fluad Pediatric
    • 14.2.5. FluBlok
  • 14.3. Product Profiles of Marketed Products
    • 14.3.1. Fluarix
    • 14.3.2. Vaxigrip
    • 14.3.3. Influvac
    • 14.3.4. Fluvax
    • 14.3.5. Agrippal

15. Seasonal Influenza Vaccine Market in Asia-Pacific - Competitive Landscape

  • 15.1. Sanofi Pasteur
  • 15.2. GlaxoSmithKline Biologicals
  • 15.3. Abbott Laboratories (Solvay Pharmaceuticals)
  • 15.4. CSL Biotherapies
  • 15.5. Novartis Vaccines
  • 15.6. Crucell N.V. (Berna Biotech)

16. Seasonal Influenza Vaccine Market in Asia-Pacific - Strategic Consolidations

  • 16.1. Overview
  • 16.2. Major Merger and Acquisition Deals, 2007-2012
    • 16.2.1. AstraZeneca Acquires Medimmune
    • 16.2.2. Sanofi-Aventis (now Sanofi) Acquires Acambis
    • 16.2.3. Mymetics Acquires Virosome Biologicals
    • 16.2.4. Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock
    • 16.2.5. Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan
    • 16.2.6. Abbott Laboratories Acquires Solvay Pharmaceuticals
    • 16.2.7. Nutri Pharma Acquires a Majority Stake in Bionor Immuno
    • 16.2.8. Johnson & Johnson Acquires Crucell
    • 16.2.9. GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals
  • 16.3. M&A Deals by Geography
  • 16.4. Major Licensing Agreements, 2007-2012
    • 16.4.1. Crucell Enters into License Agreement with Adimmune Corporation
    • 16.4.2. MedImmune Enters into Licensing Agreement with Sanofi Pasteur
    • 16.4.3. Vivalis Enters into Licensing Agreement with GlaxoSmithKline
    • 16.4.4. Vivalis Enters into Licensing Agreement with Nobilon International
    • 16.4.5. MedImmune Enters into Licensing Agreement with GlaxoSmithKline
    • 16.4.6. Hemispherx Biopharma Enters into Licensing Agreement with Biken
    • 16.4.7. MedImmune Enters into Licensing Agreement with Biken
    • 16.4.8. MedImmune Enters into Licensing Agreement with Omninvest
    • 16.4.9. OPKO Health Enters into Licensing Agreement with Academia Sinica
    • 16.4.10. Altravax Enters into Licensing Agreement with Maxygen
    • 16.4.11. Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok
    • 16.4.12. NasVax Extends its Research Agreement with Novartis
    • 16.4.13. iBio Enters into Licensing Agreement with G-Con
  • 16.5. Licensing Deals by Geography

17. Seasonal Influenza Vaccine Market in Asia-Pacific - Appendix

  • 17.1. Market Definitions
  • 17.2. Abbreviations
  • 17.3. Bibliography
  • 17.4. Research Methodology
    • 17.4.1. Coverage
    • 17.4.2. Secondary Research
    • 17.4.3. Primary Research
  • 17.5. Therapeutic Landscape
    • 17.5.2. Market Size by Geography
  • 17.6. Geographical Landscape
  • 17.7. Pipeline Analysis
  • 17.8. Competitive Landscape
    • 17.8.1. Expert Panel Validation
  • 17.9. Contact Us
  • 17.10. Disclaimer

List of Tables

  • Table 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast ($bn), 2011-2018
  • Table 2: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast by Geography ($m), 2011-2018
  • Table 3: Seasonal Influenza Vaccine Market, Australia, Revenue Forecast ($m), 2011-2018
  • Table 4: Seasonal Influenza Vaccine Market, Australia, Vaccination Cost Forecast ($), 2011-2018
  • Table 5: Seasonal Influenza Vaccine Market, Australia, Population Forecast by Age Group (million), 2011-2018
  • Table 6: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Table 7: Seasonal Influenza Vaccine Market, Australia, Vaccination Coverage Forecast by Age Group (million), 2011-2018
  • Table 8: Seasonal Influenza Vaccine Market, Australia, Number of Doses Forecast by Age Group (million), 2011-2018
  • Table 9: Seasonal Influenza Vaccine Market, China, Revenue Forecast ($m), 2011-2018
  • Table 10: Seasonal Influenza Vaccine Market, China, Vaccination Cost Forecast ($), 2011-2018
  • Table 11: Seasonal Influenza Vaccine Market, China, Population Forecast by Age Group (million), 2011-2018
  • Table 12: Seasonal Influenza Vaccine Market, China, Vaccinated Population Forecast (%), 2011-2018
  • Table 13: Seasonal Influenza Vaccine Market, China, Vaccination Coverage Forecast (million), 2011-2018
  • Table 14: Seasonal Influenza Vaccine Market, China, Number of Doses Forecast (million), 2011-2018
  • Table 15: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Forecast ($m), 2011-2018
  • Table 16: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Cost Forecast ($), 2011-2018
  • Table 17: Seasonal Influenza Vaccine Market, Hong Kong, Population Forecast by Age Group, (million), 2011-2018
  • Table 18: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Table 19: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Coverage Forecast ('000), 2011-2018
  • Table 20: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Table 21: Seasonal Influenza Vaccine Market, India, Revenue Forecast ($m), 2011-2018
  • Table 22: Seasonal Influenza Vaccine Market, India, Vaccination Cost Forecast ($), 2011-2018
  • Table 23: Seasonal Influenza Vaccine Market, Japan, Revenue Forecast ($m), 2011-2018
  • Table 24: Seasonal Influenza Vaccine Market, Japan, Vaccine Cost ($), 2011-2018
  • Table 25: Seasonal Influenza Vaccine Market, Japan, Population Forecast by Age Group (million), 2011-2018
  • Table 26: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Forecast by Age Group (%), 2011-2018
  • Table 27: Seasonal Influenza Vaccine Market, Japan, Overall Vaccination Coverage (million), 2011-2018
  • Table 28: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage by Age Group (million), 2011-2018
  • Table 29: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast (million), 2011-2018
  • Table 30: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast by Age Group (million), 2011-2018
  • Table 31: Seasonal Influenza Vaccine Market, Malaysia, Revenue Forecast ($m), 2011-2018
  • Table 32: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Cost Forecast ($), 2011-2018
  • Table 33: Seasonal Influenza Vaccine Market, Malaysia, Population Forecast by Age Group (million), 2011-2018
  • Table 34: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Table 35: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Coverage Forecast by Age Group ('000), 2011-2018
  • Table 36: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Table 37: Seasonal Influenza Vaccine Market, New Zealand, Revenue Forecast ($m), 2011-2018
  • Table 38: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Cost Forecast (%), 2011-2018
  • Table 39: Seasonal Influenza Vaccine Market, New Zealand, Population by Age Group Forecast (million), 2011-2018
  • Table 40: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Forecast (%), 2011-2018
  • Table 41: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Coverage Forecast ('000), 2011-2018
  • Table 42: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses Forecasts ('000), 2011-2018
  • Table 43: Seasonal Influenza Vaccine Market, Philippines, Revenue Forecast ($m), 2011-2018
  • Table 44: Seasonal Influenza Vaccine Market, Philippines, Vaccination Cost Forecast ($), 2011-2018
  • Table 45: Seasonal Influenza Vaccine Market, Philippines, Population Forecast (million), 2011-2018
  • Table 46: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Forecast (%), 2011-2018
  • Table 47: Seasonal Influenza Vaccine Market, Philippines, Vaccination Coverage Forecast (million), 2011-2018
  • Table 48: Seasonal Influenza Vaccine Market, Philippines, Number of Doses Forecast (million), 2011-2018
  • Table 49: Seasonal Influenza Vaccine Market, Singapore, Revenue Forecast ($m), 2011-2018
  • Table 50: Seasonal Influenza Vaccine Market, Singapore, Vaccination Cost Forecast ($), 2011-2018
  • Table 51: Seasonal Influenza Vaccine Market, Singapore, Population Forecast by Age Group (million), 2011-2018
  • Table 52: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Table 53: Seasonal Influenza Vaccine Market, Singapore, Vaccination Coverage Forecast ('000), 2011-2018
  • Table 54: Seasonal Influenza Vaccine Market, Singapore, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Table 55: Seasonal Influenza Vaccine Market, Taiwan, Revenue Forecast ($m), 2011-2018
  • Table 56: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Cost Forecast ($), 2011-2018
  • Table 57: Seasonal Influenza Vaccine Market, Taiwan, Population Forecast by Age Group (million), 2011-2018
  • Table 58: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Table 59: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Coverage Forecast by Age Group (million), 2011-2018
  • Table 60: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses Forecast by Age Group (million), 2011-2018
  • Table 61: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Filed, 2012
  • Table 62: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase III, 2012
  • Table 63: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase II, 2012
  • Table 64: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Phase I, 2012
  • Table 65: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Preclinical, 2012
  • Table 66: Seasonal Influenza Vaccine Market, APAC Region, Pipeline, Discovery Phase, 2012
  • Table 67: Seasonal Influenza Vaccine Market, APAC Region, Most Promising Vaccines in Clinical Development, 2012
  • Table 68: Seasonal Influenza Vaccine Market, APAC Region, Major M&A Deals, 2007-2012

List of Figures

  • Figure 1: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast ($m), 2011-2018
  • Figure 2: Seasonal Influenza Vaccine Market, APAC Region, Revenue Forecast by Geography ($bn), 2011-2018
  • Figure 3: Seasonal Influenza Vaccine Market, Australia, Regulatory Authorities, 2012
  • Figure 4: Seasonal Influenza Vaccine Market, Australia, Drug Approval Process, 2011
  • Figure 5: Seasonal Influenza Vaccine Market, Australia, Revenue Forecast ($m), 2011-2018
  • Figure 6: Seasonal Influenza Vaccine Market, Australia, Vaccination Cost Forecast ($), 2011-2018
  • Figure 7: Seasonal Influenza Vaccine Market, Australia, Population Forecast by Age Group (million), 2011-2018
  • Figure 8: Seasonal Influenza Vaccine Market, Australia, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Figure 9: Seasonal Influenza Vaccine Market, Australia, Number of Doses Forecast by Age Group (million), 2011-2018
  • Figure 10: Seasonal Influenza Vaccine Market, Australia, Drivers and Barriers, 2012
  • Figure 11: Seasonal Influenza Vaccine Market, China, Regulatory Authorities, 2011
  • Figure 12: Seasonal Influenza Vaccine Market, China, New Drug Registration Process, 2011
  • Figure 13: Seasonal Influenza Vaccine Market, China, Revenue Forecast ($m), 2011-2018
  • Figure 14: Seasonal Influenza Vaccine Market, China, Vaccination Cost Forecast ($), 2011-2018
  • Figure 15: Seasonal Influenza Vaccine Market, China, Population Forecast by Age Group (million), 2011-2018
  • Figure 16: Seasonal Influenza Vaccine Market, China, Vaccinated Population Forecast (%), 2011-2018
  • Figure 17: Seasonal Influenza Vaccine Market, China, Number of Doses Forecast (million), 2011-2018
  • Figure 18: Seasonal Influenza Vaccine Market, China, Drivers and Barriers, 2012
  • Figure 19: Seasonal Influenza Vaccine Market, Hong Kong, Regulatory Authorities, 2011
  • Figure 20: Seasonal Influenza Vaccine Market, Hong Kong, Drug Approval Process, 2011
  • Figure 21: Seasonal Influenza Vaccine Market, Hong Kong, Revenue Forecast ($m), 2011-2018
  • Figure 22: Seasonal Influenza Vaccine Market, Hong Kong, Vaccination Cost Forecast ($), 2011-2018
  • Figure 23: Seasonal Influenza Vaccine Market, Hong Kong, Population Forecast by Age Group (million), 2011-2018
  • Figure 24: Seasonal Influenza Vaccine Market, Hong Kong, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Figure 25: Seasonal Influenza Vaccine Market, Hong Kong, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Figure 26: Seasonal Influenza Vaccine Market, Hong Kong, Market Share by Company (%), 2012
  • Figure 27: Seasonal Influenza Vaccine Market, Hong Kong, Drivers and Barriers, 2012
  • Figure 28: Seasonal Influenza Vaccine Market, India, Regulatory Authority, 2011
  • Figure 29: Seasonal Influenza Vaccine Market, India, Common Technical Document Application, 2011
  • Figure 30: Seasonal Influenza Vaccine Market, India, Drug Approval Process, 2011
  • Figure 31: Seasonal Influenza Vaccine Market, India, Revenue Forecast ($m), 2011-2018
  • Figure 32: Seasonal Influenza Vaccine Market, India, Vaccination Cost Forecast ($), 2011-2018
  • Figure 33: Seasonal Influenza Vaccine Market, India, Drivers and Barriers, 2012
  • Figure 34: Seasonal Influenza Vaccine Market, Japan, Regulatory Authorities, 2012
  • Figure 35: Seasonal Influenza Vaccine Market, Japan, Drug Approval Process, 2012
  • Figure 36: Seasonal Influenza Vaccine Market, Japan, Revenue Forecast ($m), 2011-2018
  • Figure 37: Seasonal Influenza Vaccine Market, Japan, Population Forecast by Age Group (million), 2011-2018
  • Figure 38: Seasonal Influenza Vaccine Market, Japan, Vaccination Coverage Forecast by Age Group (%), 2011-2018
  • Figure 39: Seasonal Influenza Vaccine Market, Japan, Number of Doses Forecast by Age Group (million), 2011-2018
  • Figure 40: Seasonal Influenza Vaccine Market, Japan, Drivers and Barriers, 2012
  • Figure 41: Seasonal Influenza Vaccine Market, Malaysia, Regulatory Authorities, 2011
  • Figure 42: Seasonal Influenza Vaccine Market, Malaysia, Drug Approval Process, 2011
  • Figure 43: Seasonal Influenza Vaccine Market, Malaysia, Revenue Forecast ($m), 2011-2018
  • Figure 44: Seasonal Influenza Vaccine Market, Malaysia, Vaccination Cost Forecast ($), 2011-2018
  • Figure 45: Seasonal Influenza Vaccine Market, Malaysia, Population Forecast by Age Group (million), 2011-2018
  • Figure 46: Seasonal Influenza Vaccine Market, Malaysia, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Figure 47: Seasonal Influenza Vaccine Market, Malaysia, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Figure 48: Seasonal Influenza Vaccine Market, Malaysia, Market Share by Company (%), 2012
  • Figure 49: Seasonal Influenza Vaccine Market, Malaysia, Drivers and Barriers, 2012
  • Figure 50: Seasonal Influenza Vaccine Market, New Zealand, Regulatory Authorities, 2011
  • Figure 51: Seasonal Influenza Vaccine Market, New Zealand, Drug Approval Process, 2011
  • Figure 52: Seasonal Influenza Vaccine Market, New Zealand, Revenue Forecast ($m), 2011-2018
  • Figure 53: Seasonal Influenza Vaccine Market, New Zealand, Vaccination Cost Forecast ($), 2011-2018
  • Figure 54: Seasonal Influenza Vaccine Market, New Zealand, Population by Age Group Forecast (million), 2011-2018
  • Figure 55: Seasonal Influenza Vaccine Market, New Zealand, Vaccinated Population Forecast (%), 2011-2018
  • Figure 56: Seasonal Influenza Vaccine Market, New Zealand, Number of Doses Forecast ('000), 2011-2018
  • Figure 57: Seasonal Influenza Vaccine Market, New Zealand, Market Share by Company (%), 2012
  • Figure 58: Seasonal Influenza Vaccine Market, New Zealand, Drivers and Barriers, 2012
  • Figure 59: Seasonal Influenza Vaccine Market, Philippines, Regulatory Authorities, 2011
  • Figure 60: Seasonal Influenza Vaccine Market, Philippines, Drug Approval Process, 2011
  • Figure 61: Seasonal Influenza Vaccine Market, Philippines, Revenue Forecast ($m), 2011-2018
  • Figure 62: Seasonal Influenza Vaccine Market, Philippines, Vaccination Cost Forecast ($m), 2011-2018
  • Figure 63: Seasonal Influenza Vaccine Market, Philippines, Population Forecast (million), 2011-2018
  • Figure 64: Seasonal Influenza Vaccine Market, Philippines, Vaccinated Population Forecast (%), 2011-2018
  • Figure 65: Seasonal Influenza Vaccine Market, Philippines, Number of Doses Forecast (million), 2011-2018
  • Figure 66: Seasonal Influenza Vaccine Market, Philippines, Market Share by Company (%), 2012
  • Figure 67: Seasonal Influenza Vaccine Market, Philippines, Drivers and Barriers, 2012
  • Figure 68: Seasonal Influenza Vaccine Market, Singapore, Regulatory Authorities, 2011
  • Figure 69: Seasonal Influenza Vaccine Market, Singapore, Drug Approval Process, 2011
  • Figure 70: Seasonal Influenza Vaccine Market, Singapore, Revenue Forecast ($m), 2011-2018
  • Figure 71: Seasonal Influenza Vaccine Market, Singapore, Vaccination Cost Forecast ($), 2011-2018
  • Figure 72: Seasonal Influenza Vaccine Market, Singapore, Population Forecast by Age Group (million), 2011-2018
  • Figure 73: Seasonal Influenza Vaccine Market, Singapore, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Figure 74: Seasonal Influenza Vaccine Market, Singapore, Number of Doses Forecast by Age Group ('000), 2011-2018
  • Figure 75: Seasonal Influenza Vaccine Market, Singapore, Market Share by Company (%), 2012
  • Figure 76: Seasonal Influenza Vaccine Market, Singapore, Drivers and Barriers, 2012
  • Figure 77: Seasonal Influenza Vaccine Market, Taiwan, Regulatory Authorities, 2011
  • Figure 78: Seasonal Influenza Vaccine Market, Taiwan, Drug Approval Process, 2011
  • Figure 79: Seasonal Influenza Vaccine Market, Taiwan, Revenue Forecast ($m), 2011-2018
  • Figure 80: Seasonal Influenza Vaccine Market, Taiwan, Vaccination Cost Forecast ($), 2011-2018
  • Figure 81: Seasonal Influenza Vaccine Market, Taiwan, Population Forecast by Age Group (million), 2011-2018
  • Figure 82: Seasonal Influenza Vaccine Market, Taiwan, Vaccinated Population Forecast by Age Group (%), 2011-2018
  • Figure 83: Seasonal Influenza Vaccine Market, Taiwan, Number of Doses Forecast by Age Group (million), 2011-2018
  • Figure 84: Seasonal Influenza Vaccine Market, Taiwan, Market Share by Company (%), 2012
  • Figure 85: Seasonal Influenza Vaccine Market, Taiwan, Drivers and Barriers, 2012
  • Figure 86: Seasonal Influenza Vaccine Market, APAC Region, Pipeline by Phase (%), 2012
  • Figure 87: Seasonal Influenza Vaccine Market, APAC Region, M&A Deals by Geography (%), 2007-2012
  • Figure 88: Seasonal Influenza Vaccine Market, APAC Region, Licensing Agreements by Geography, (%), 2007-2012
  • Figure 89: GBI Research Market Forecasting Model
Back to Top